Skip to ContentSkip to Navigation
How to find us R.G.P. Gijtenbeek, MSc


Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Early treatment response may predict long-term mepolizumab benefit in severe asthma

Read more